19:51 , Oct 5, 2018 |  BC Week In Review  |  Financial News

Aldeyra, Nightstar price follow-ons

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) and Nightstar Therapeutics plc (NASDAQ:NITE) each priced follow-ons Sept. 27, raising a total of about $144 million. Aldeyra raised $72.2 million through the sale of 5.3 million shares at $13.75 in...
21:25 , Sep 28, 2018 |  BC Extra  |  Financial News

Aldeyra, Nightstar price follow-ons

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) and Nightstar Therapeutics plc (NASDAQ:NITE) each priced follow-ons Thursday, raising a total of about $144 million. Aldeyra raised $72.2 million through the sale of 5.3 million shares at $13.75 in a...
17:33 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

Aldeyra planning Phase III program for dry eye disease therapy

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) reported that reproxalap (ADX-102) significantly reduced ocular dryness and discomfort in a Phase IIb trial to treat dry eye disease. The company plans to start Phase III testing of the candidate...
16:53 , Sep 26, 2018 |  BC Extra  |  Clinical News

Aldeyra planning Phase III program for dry eye disease therapy

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) added $3.45 (35%) to $13.35 on Wednesday after reporting that reproxalap (ADX-102) significantly reduced ocular dryness and discomfort in a Phase IIb trial to treat dry eye disease. The company plans...
20:52 , Jul 31, 2018 |  BC Extra  |  Company News

Management tracks: Canbridge, Retrophin

Canbridge Life Sciences Ltd. (Beijing, China) hired May Orfali as CMO. She succeeds interim CMO Mark Goldberg. Orfali was executive director of global product development at Pfizer Inc. (NYSE:PFE). Rare disease company Retrophin Inc. (NASDAQ:RTRX)...
21:20 , May 11, 2018 |  BC Extra  |  Company News

Management tracks: Synlogic, Akari

Synlogic Inc. (NASDAQ:SYBX) said President and CEO Jose Carlos Gutiérrez-Ramos has resigned. CMO Aoife Brennan will serve as interim president and CEO while the synthetic biology company seeks a successor. Autoimmune and inflammatory disease company...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
23:29 , Oct 6, 2017 |  BioCentury  |  Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
19:55 , Sep 22, 2017 |  BC Week In Review  |  Financial News

Aldeyra raises $28.8M follow-on

Aldeyra Therapeutics Inc. (NASDAQ:ALDX), which focuses on diseases related to aldehydes, raised $28.8 million through the sale of 4 million shares at $7.25 in a follow-on underwritten by Cantor Fitzgerald and Laidlaw. The price is...
19:05 , Sep 19, 2017 |  BC Extra  |  Financial News

Aldeyra raises $25 million in follow-on

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) raised $25 million through the sale of 3.5 million shares at $7.25 in a follow-on underwritten by Cantor Fitzgerald and Laidlaw. The price is a 20% discount to Aldeyra’s close of...